tetano
Editor, Senior Moderator
Vaccine
. 2021 Dec 2;S0264-410X(21)01473-0.
doi: 10.1016/j.vaccine.2021.11.028. Online ahead of print.
AZD1222 (ChAdOx1 nCov-19): A Single-Dose biodistribution study in mice
Richard Stebbings[SUP] 1 [/SUP], Gillian Armour[SUP] 2 [/SUP], Vivian Pettis[SUP] 3 [/SUP], Joanne Goodman[SUP] 4 [/SUP]
Affiliations
Abstract
Biodistribution studies of adenovirus-based vaccines support their clinical development by evaluating their spread and persistence following in vivo administration. AZD1222 (ChAdox1 nCov-19) is a replication-deficient non-human adenovirus-vectored vaccine for coronavirus disease 2019. In this nonclinical study, the biodistribution of AZD1222 was assessed in mice for 29 days following intramuscular injection. Results show that AZD1222 was safe and well tolerated, with a spread that was largely confined to administration sites and the proximal sciatic nerve, with low levels observed in sites that are involved in rapid clearance of particulates by the reticuloendothelial system. Accordingly, levels of AZD1222 decreased from Day 2 to Day 29, indicating clearance. There were no quantifiable levels of AZD1222 in the blood, brain, spinal cord, and reproductive tissue, suggesting a lack of widespread or long-term distribution of AZD1222 vector DNA throughout the body following its administration.
Keywords: AZD1222; Biodistribution; COVID-19; ChAdOx1 nCov-19.
. 2021 Dec 2;S0264-410X(21)01473-0.
doi: 10.1016/j.vaccine.2021.11.028. Online ahead of print.
AZD1222 (ChAdOx1 nCov-19): A Single-Dose biodistribution study in mice
Richard Stebbings[SUP] 1 [/SUP], Gillian Armour[SUP] 2 [/SUP], Vivian Pettis[SUP] 3 [/SUP], Joanne Goodman[SUP] 4 [/SUP]
Affiliations
- PMID: 34865878
- DOI: 10.1016/j.vaccine.2021.11.028
Abstract
Biodistribution studies of adenovirus-based vaccines support their clinical development by evaluating their spread and persistence following in vivo administration. AZD1222 (ChAdox1 nCov-19) is a replication-deficient non-human adenovirus-vectored vaccine for coronavirus disease 2019. In this nonclinical study, the biodistribution of AZD1222 was assessed in mice for 29 days following intramuscular injection. Results show that AZD1222 was safe and well tolerated, with a spread that was largely confined to administration sites and the proximal sciatic nerve, with low levels observed in sites that are involved in rapid clearance of particulates by the reticuloendothelial system. Accordingly, levels of AZD1222 decreased from Day 2 to Day 29, indicating clearance. There were no quantifiable levels of AZD1222 in the blood, brain, spinal cord, and reproductive tissue, suggesting a lack of widespread or long-term distribution of AZD1222 vector DNA throughout the body following its administration.
Keywords: AZD1222; Biodistribution; COVID-19; ChAdOx1 nCov-19.